Literature DB >> 29260505

Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Fawzy Elbarbry1.   

Abstract

After more than six decades of its use as the mainstay antibiotic for the treatment of multidrug-resistant Gram-positive bacterial infections, dosing and monitoring of vancomycin therapy have not been optimized. The current vancomycin therapeutic guidelines recommend empiric doses of 15-20 mg/kg administered by intermittent infusion every 8-12 h in patients with normal kidney function. Additionally, the guidelines recommend trough concentration of 15-20 mg/L as a therapeutic goal for adult patients with severe infections. This review critically discusses the current guidelines considering the basic pharmacokinetics and pharmacodynamics of vancomycin and the recent published reports from clinical studies. More in-depth discussion will be focused on (1) providing evidence of advantages of administering vancomycin by continuous infusion compared to intermittent infusion; (2) revising the current practice of trough-only monitoring versus the area under concentration-time curve (AUC); and (3) assessing the current practice of weight-based dosing versus AUC-based dosing. Using the gathered information presented in this paper, two user-friendly and scientifically based dosing strategies are proposed to improve the efficiency of vancomycin dosing while avoiding the risk of nephrotoxicity and minimizing the cost of therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29260505     DOI: 10.1007/s13318-017-0456-4

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  43 in total

Review 1.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

2.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

3.  Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.

Authors:  Ravina Kullar; Susan L Davis; Thomas N Taylor; Keith S Kaye; Michael J Rybak
Journal:  Pharmacotherapy       Date:  2012-03       Impact factor: 4.705

4.  Performance of a vancomycin dosage regimen developed for obese patients.

Authors:  David C Reynolds; Laura H Waite; Donald P Alexander; C Andrew DeRyke
Journal:  Am J Health Syst Pharm       Date:  2012-06-01       Impact factor: 2.637

Review 5.  AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.

Authors:  Daniel L Brown; Christina D Lalla; Andrew J Masselink
Journal:  Ther Drug Monit       Date:  2013-08       Impact factor: 3.681

6.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Vancomycin: we can't get there from here.

Authors:  Nimish Patel; Manjunath P Pai; Keith A Rodvold; Ben Lomaestro; George L Drusano; Thomas P Lodise
Journal:  Clin Infect Dis       Date:  2011-04-15       Impact factor: 9.079

Review 8.  Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis.

Authors:  Jing-Jing Hao; Han Chen; Jian-Xin Zhou
Journal:  Int J Antimicrob Agents       Date:  2015-11-24       Impact factor: 5.283

Review 9.  Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Authors:  Manjunath P Pai; Michael Neely; Keith A Rodvold; Thomas P Lodise
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

10.  Stability of vancomycin hydrochloride in 5% dextrose and 0.9% sodium chloride injections.

Authors:  V Das Gupta; K R Stewart; S Nohria
Journal:  Am J Hosp Pharm       Date:  1986-07
View more
  9 in total

1.  Electrochemical Aptamer-Based Sensors for Improved Therapeutic Drug Monitoring and High-Precision, Feedback-Controlled Drug Delivery.

Authors:  Philippe Dauphin-Ducharme; Kyungae Yang; Netzahualcóyotl Arroyo-Currás; Kyle L Ploense; Yameng Zhang; Julian Gerson; Martin Kurnik; Tod E Kippin; Milan N Stojanovic; Kevin W Plaxco
Journal:  ACS Sens       Date:  2019-10-15       Impact factor: 7.711

2.  Pharmacokinetics of and maintenance dose recommendations for vancomycin in severe pneumonia patients undergoing continuous venovenous hemofiltration with the combination of predilution and postdilution.

Authors:  Qiang Li; Fenghua Liang; Ling Sang; Pengpeng Li; Bijun Lv; Lu Tan; Xiaoqing Liu; Wenying Chen
Journal:  Eur J Clin Pharmacol       Date:  2019-11-16       Impact factor: 2.953

3.  Effects of Vancomycin on Persistent Pain-Stimulated and Pain-Depressed Behaviors in Female Fischer Rats With or Without Voluntary Access to Running Wheels.

Authors:  Emily Payne; Kylee Harrington; Philomena Richard; Rebecca Brackin; Ravin Davis; Sarah Couture; Jacob Liff; Francesca Asmus; Elizabeth Mutina; Anyssa Fisher; Denise Giuvelis; Sebastien Sannajust; Bahman Rostama; Tamara King; Lisa M Mattei; Jung-Jin Lee; Elliot S Friedman; Kyle Bittinger; Meghan May; Glenn W Stevenson
Journal:  J Pain       Date:  2021-05-21       Impact factor: 5.820

4.  Vancomycin Dosage and Its Association with Clinical Outcomes in Pediatric Patients with Gram-Positive Bacterial Infections.

Authors:  Sooyoung Shin; Hyun Joo Jung; Sang-Min Jeon; Young-Joon Park; Jung-Woo Chae; Hwi-Yeol Yun
Journal:  Risk Manag Healthc Policy       Date:  2020-06-29

5.  Tibial bone and soft-tissue concentrations following combination therapy with vancomycin and meropenem - evaluated by microdialysis in a porcine model : should patients with open fractures have higher doses of antibiotics?

Authors:  Sofus Ørbæk Vittrup; Pelle Hanberg; Martin Bruun Knudsen; Sara Kousgaard Tøstesen; Josephine Olsen Kipp; Jakob Hansen; Nis Pedersen Jørgensen; Maiken Stilling; Mats Bue
Journal:  Bone Joint Res       Date:  2022-02       Impact factor: 5.853

6.  Therapeutic drug monitoring of cefepime in a non-critically ill population: retrospective assessment and potential role for model-based dosing.

Authors:  Véronique Suttels; Pascal André; Yann Thoma; François Veuve; Laurent Decosterd; Benoît Guery; Thierry Buclin
Journal:  JAC Antimicrob Resist       Date:  2022-04-21

7.  Continuous infusion versus intermittent infusion of vancomycin in critically ill patients undergoing continuous venovenous hemofiltration: a prospective interventional study.

Authors:  Jinhui Xu; Lufen Duan; Jiahui Li; Fang Chen; Xiaowen Xu; Jian Lu; Zhiwei Zhuang; Yifei Cao; Yunlong Yuan; Xin Liu; Jiantong Sun; Qin Zhou; Lu Shi; Lian Tang
Journal:  BMC Infect Dis       Date:  2022-08-02       Impact factor: 3.667

8.  Influence of antibiotic treatment on the detection of S. aureus in whole blood following pathogen enrichment.

Authors:  Matthias Pilecky; Anita Schildberger; Ludwig Knabl; Dorothea Orth-Höller; Viktoria Weber
Journal:  BMC Microbiol       Date:  2019-08-06       Impact factor: 3.605

9.  Experience of Vancomycin Therapeutic Drug Monitoring in Two Multidisciplinary Hospitals in Latvia.

Authors:  Inga Mauliņa; Karīna Darbiniece; Lāsma Miķelsone-Jansone; Renārs Erts; Dace Bandere; Angelika Krūmiņa
Journal:  Medicina (Kaunas)       Date:  2022-03-02       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.